select a format

Single User License
USD 2000 INR 128280
Site License
USD 4000 INR 256560
Corporate User License
USD 6000 INR 384840

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Essential Tremor-Pipeline Review, H2 2016

Essential Tremor-Pipeline Review, H2 2016


  • Products Id :- GMDHC8799IDB
  • |
  • Pages: 48
  • |
  • December 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Essential Tremor-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Essential Tremor-Pipeline Review, H2 2016, provides an overview of the Essential Tremor (Central Nervous System) pipeline landscape.

Essential tremor is a type of involuntary shaking movement in which no cause can be identified. Involuntary means you shake without trying to do so. Essential tremor is the most common type of tremor. The exact cause for essential tremor is unknown. Tremors occur when there is a problem with the nerves that supply certain muscles. The tremor is more likely to be noticed in the hands, but may affect the arms, head, eyelids, or other muscles. The tremor rarely affects the legs or feet. Treatment may not be needed unless the tremors interfere with your daily activities or cause embarrassment.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Essential Tremor-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Essential Tremor (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Essential Tremor (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Essential Tremor and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Discovery stages are 2, 2 and 2 respectively.Essential Tremor.

Essential Tremor (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Essential Tremor (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Essential Tremor (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Essential Tremor (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Essential Tremor (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Essential Tremor (Central Nervous System)

Reasons To Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Essential Tremor (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Essential Tremor (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Essential Tremor Overview 6

Therapeutics Development 7

Pipeline Products for Essential Tremor-Overview 7

Essential Tremor-Therapeutics under Development by Companies 8

Essential Tremor-Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Essential Tremor-Products under Development by Companies 11

Essential Tremor-Companies Involved in Therapeutics Development 12

Merz Pharma GmbH & Co KgaA 12

Neurocrine Biosciences Inc 13

Sage Therapeutics Inc 14

Essential Tremor-Therapeutics Assessment 15

Assessment by Monotherapy Products 15

Assessment by Target 16

Assessment by Mechanism of Action 18

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Drug Profiles 24

incobotulinumtoxin A-Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

NBI-640756-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

SAGE-217-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

sepranolone-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Small Molecules to Antagonize GPCR for Central Nervous System Diseases-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Small Molecules to Target Ion Channels for CNS Disorders-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Essential Tremor-Dormant Projects 40

Essential Tremor-Discontinued Products 41

Essential Tremor-Product Development Milestones 42

Featured News & Press Releases 42

Apr 17, 2016: Sage Therapeutics Expands Scientific, Clinical and Burden of Illness Data for SAGE-547 in SRSE and Essential Tremor at the 2016 American Academy of Neurology Annual Meeting 42

Nov 04, 2015: Neurocrine Biosciences Announces Expansion of its Clinical Pipeline 43

Sep 03, 2015: SAGE Therapeutics Announces Results From Successful Exploratory Trial in Essential Tremor 44

Oct 23, 2014: SAGE Therapeutics Initiates Exploratory Study of SAGE-547 in Essential Tremor 46

Appendix 47

Methodology 47

Coverage 47

Secondary Research 47

Primary Research 47

Expert Panel Validation 47

Contact Us 47

Disclaimer 48

List of Figures

Number of Products under Development for Essential Tremor, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Assessment by Monotherapy Products, H2 2016 15

Number of Products by Targets, H2 2016 16

Number of Products by Stage and Targets, H2 2016 16

Number of Products by Mechanism of Actions, H2 2016 18

Number of Products by Stage and Mechanism of Actions, H2 2016 18

Number of Products by Routes of Administration, H2 2016 20

Number of Products by Stage and Routes of Administration, H2 2016 20

Number of Products by Molecule Types, H2 2016 22

Number of Products by Stage and Molecule Types, H2 2016 22

List of Tables

Number of Products under Development for Essential Tremor, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Development, H2 2016 10

Products under Development by Companies, H2 2016 11

Essential Tremor-Pipeline by Merz Pharma GmbH & Co KgaA, H2 2016 12

Essential Tremor-Pipeline by Neurocrine Biosciences Inc, H2 2016 13

Essential Tremor-Pipeline by Sage Therapeutics Inc, H2 2016 14

Assessment by Monotherapy Products, H2 2016 15

Number of Products by Stage and Target, H2 2016 17

Number of Products by Stage and Mechanism of Action, H2 2016 19

Number of Products by Stage and Route of Administration, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 23

Essential Tremor-Dormant Projects, H2 2016 40

Essential Tremor-Discontinued Products, H2 2016 41

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Merz Pharma GmbH & Co KgaA, Neurocrine Biosciences Inc, Sage Therapeutics Inc

Essential Tremor Therapeutic Products under Development, Key Players in Essential Tremor Therapeutics, Essential Tremor Pipeline Overview, Essential Tremor Pipeline, Essential Tremor Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com